Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Nov;30(5):743-8.
doi: 10.1128/AAC.30.5.743.

Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents

Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents

J L Vildé et al. Antimicrob Agents Chemother. 1986 Nov.

Abstract

The activity of serial concentrations of different antimicrobial agents on the multiplication of Legionella pneumophila within human monocyte-derived macrophages was studied. The results led to the definition of a minimal extracellular concentration inhibiting intracellular multiplication (MIEC). According to the MIECs, the antimicrobial agents tested were classified in three groups: very active (MIEC less than or equal to 0.06 microgram/ml), such as erythromycin, rifampin, and pefloxacin; active (1 microgram/ml greater than or equal to MIEC greater than or equal to 0.1 microgram/ml), such as sulfamethoxazole-trimethoprim or doxycycline; and ineffective, such as cefoxitin, which was not active within macrophages at as high as 64 micrograms/ml despite a low MIC (0.2 microgram/ml) on bacterial charcoal-yeast extract agar. The activity of netilmicin was difficult to assess because of its effect on extracellular legionellae. Combinations of erythromycin with rifampin and pefloxacin with erythromycin, rifampin, doxycycline, or netilmicin showed an additive effect and no antagonism. These results obtained in a cellular model are in agreement with the efficacy of antimicrobial agents in experimental infections and in Legionnaires disease. They sustain clinical interest in the new quinolones, such as pefloxacin, and in combinations of antimicrobial agents for the treatment of Legionnaires disease.

PubMed Disclaimer

References

    1. N Engl J Med. 1977 Dec 1;297(22):1189-97 - PubMed
    1. Antimicrob Agents Chemother. 1978 Mar;13(3):419-22 - PubMed
    1. Antimicrob Agents Chemother. 1978 Jan;13(1):78-80 - PubMed
    1. Antimicrob Agents Chemother. 1979 Nov;16(5):561-4 - PubMed
    1. J Clin Invest. 1980 Sep;66(3):441-50 - PubMed

Publication types

MeSH terms

LinkOut - more resources